bluebird bio (NASDAQ:BLUE) Upgraded to Sell at StockNews.com

StockNews.com upgraded shares of bluebird bio (NASDAQ:BLUE) to a sell rating in a research note issued to investors on Friday morning.

Other equities analysts also recently issued research reports about the stock. HSBC began coverage on shares of bluebird bio in a research note on Wednesday, September 6th. They issued a buy rating and a $4.21 price objective for the company. Raymond James upped their price objective on shares of bluebird bio from $10.00 to $13.00 and gave the company an outperform rating in a research note on Wednesday, November 8th. Cantor Fitzgerald began coverage on shares of bluebird bio in a research note on Tuesday, October 17th. They issued a neutral rating for the company. Finally, Wedbush restated a neutral rating and issued a $5.00 price objective (down previously from $7.00) on shares of bluebird bio in a research note on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, bluebird bio has an average rating of Hold and a consensus price target of $7.62.

bluebird bio Trading Up 12.0 %

Shares of BLUE stock opened at $3.83 on Friday. The firm has a fifty day moving average price of $3.07 and a 200 day moving average price of $3.46. The company has a market cap of $418.76 million, a P/E ratio of -5.18 and a beta of 0.87. bluebird bio has a 12 month low of $2.52 and a 12 month high of $8.58.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.03. bluebird bio had a negative net margin of 419.64% and a negative return on equity of 34.32%. The firm had revenue of $12.40 million during the quarter, compared to the consensus estimate of $13.56 million. During the same quarter in the previous year, the firm posted ($0.92) earnings per share. The company’s revenue was up 17364.8% compared to the same quarter last year. On average, equities analysts forecast that bluebird bio will post -1.83 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BLUE. US Bancorp DE raised its holdings in bluebird bio by 885.7% during the second quarter. US Bancorp DE now owns 7,511 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 6,749 shares in the last quarter. Stifel Financial Corp purchased a new position in bluebird bio during the third quarter worth about $32,000. Aigen Investment Management LP purchased a new position in bluebird bio during the third quarter worth about $34,000. Victory Capital Management Inc. purchased a new position in bluebird bio during the first quarter worth about $36,000. Finally, Johnson Investment Counsel Inc. purchased a new position in bluebird bio during the third quarter worth about $40,000. 87.43% of the stock is owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.